Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomised, Multicentre Study to Assess the Dose Level of Multiple THR-687 Injections and to Evaluate the Efficacy and Safety of THR-687 Versus Aflibercept for the Treatment of Diabetic Macular Oedema (DME)

NCT05063734 is registered in ClinicalTrials.gov with Oxurion as lead sponsor.

NCT NCT05063734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05063734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomised, Multicentre Study to Assess the Dose Level of Multiple THR-687 Injections and to Evaluate the Efficacy and Safety of THR-687 Versus Aflibercept for the Treatment of Diabetic Macular Oedema (DME)
Lead sponsor
Oxurion
Phase
Phase 2
Overall status
Terminated
Start date
August 27, 2021
Completion date
June 29, 2022
Enrollment
16 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, diabetic macular edema, diabetic retinopathy